CARIBOU BIOSCIENCES INC (CRBU) Stock Price & Overview
NASDAQ:CRBU • US1420381089
The current stock price of CRBU is 2.03 USD. Today CRBU is up by 3.05%. In the past month the price increased by 24.54%. In the past year, price increased by 100.99%.
CRBU Key Statistics
- Market Cap
- 189.744M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.59
- Dividend Yield
- N/A
CRBU Stock Performance
CRBU Stock Chart
CRBU Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CRBU. When comparing the yearly performance of all stocks, CRBU is one of the better performing stocks in the market, outperforming 92.96% of all stocks.
CRBU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRBU. The financial health of CRBU is average, but there are quite some concerns on its profitability.
CRBU Earnings
On March 5, 2026 CRBU reported an EPS of -0.28 and a revenue of 3.94M. The company beat EPS expectations (11.45% surprise) and beat revenue expectations (53.17% surprise).
CRBU Forecast & Estimates
15 analysts have analysed CRBU and the average price target is 11.33 USD. This implies a price increase of 458.29% is expected in the next year compared to the current price of 2.03.
For the next year, analysts expect an EPS growth of 13.8% and a revenue growth 5.37% for CRBU
CRBU Groups
Sector & Classification
CRBU Financial Highlights
Over the last trailing twelve months CRBU reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS increased by 3.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.58% | ||
| ROE | -110.77% | ||
| Debt/Equity | 0 |
CRBU Ownership
CRBU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 401.392B | ||
| AMGN | AMGEN INC | 16.45 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.72 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRBU
Company Profile
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 147 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Company Info
IPO: 2021-07-23
CARIBOU BIOSCIENCES INC
2929 7Th Street, Ste 120
Berkeley CALIFORNIA US
Employees: 147
Phone: 15109826030
CARIBOU BIOSCIENCES INC / CRBU FAQ
Can you describe the business of CARIBOU BIOSCIENCES INC?
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 147 full-time employees. The company went IPO on 2021-07-23. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. The company is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
What is the current price of CRBU stock?
The current stock price of CRBU is 2.03 USD. The price increased by 3.05% in the last trading session.
What is the dividend status of CARIBOU BIOSCIENCES INC?
CRBU does not pay a dividend.
How is the ChartMill rating for CARIBOU BIOSCIENCES INC?
CRBU has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is CRBU stock listed?
CRBU stock is listed on the Nasdaq exchange.
Who owns CARIBOU BIOSCIENCES INC?
You can find the ownership structure of CARIBOU BIOSCIENCES INC (CRBU) on the Ownership tab.
What is the Short Interest ratio of CARIBOU BIOSCIENCES INC (CRBU) stock?
The outstanding short interest for CARIBOU BIOSCIENCES INC (CRBU) is 9.25% of its float.